ABBV · News · 20261102N
Revenue Performance and Mix
AbbVie Inc. · 2026-11-02 · Importance 29 · Surprise 22 · No source text
AbbVie’s third-quarter 2026 sales rose 10.3% year over year to $17.4 billion. Sales were slightly above the cited analyst estimate of $17.34 billion. The report attributed the quarter’s growth to immunology and neuroscience, including SKYRIZI, RINVOQ, and VRAYLAR, which each posted double-digit revenue increases.
Key facts
- AbbVie’s Q3 2026 sales were $17.4 billion, up 10.3% year over year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.6% | AbbVie’s Q3 2026 sales were $17.4 billion, up 10.3% year over year. |